Alemtuzumab

N/A

Report date: 2023/05/05 17:08:50
First In Class

Base Information

Drug NameAlemtuzumab
Drug Alias Name阿仑单抗MabKampatAnti-CD52 monoclonal antibody阿仑珠单抗阿来组单抗 +[14] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCAMPATH-1 antigen inhibitors
TargetsCAMPATH-1 antigen
Therapy Area/IndicationsRejection of renal transplantationBone marrow transplant rejectionGraft Rejection +[33] 
Global Approved IndicationsMultiple SclerosisLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2001/05/07
Country/TerritoryCzechiaBelgiumCanada +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesGenzyme CorpBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesSanofi BelgiumSanofiColumbia University +[5] 
Inactive CompaniesDana-Farber Cancer InstituteCabyc SlCharite University, Berlin, Germany +[15] 
Active IndicationsAnemia, Sickle CellMultiple SclerosisLymphoma, T-Cell, Peripheral +[8] 
Inactive IndicationsRejection of renal transplantationBone marrow transplant rejectionGraft Rejection +[25] 

Other Information

ATC CodeL04AG06
Related LinksWikipediaDrugBankKEGG